3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

72.75 +0.37 ( +0.51% ) 10:12 5/23/18 Pricing delayed 20 minutes

Volume 51,209

Recent News

See All
May 14, 2018 Nevro Recognized as a "Best Place to Work" in the Bay Area
"Fun, Collaborative, Fast-Paced" Top List of Words Nevro Team Members Use to Describe Work Environment Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it has been named one of the "Best Places to Work" in the Bay Area by the San Francisco Business Times and the Silicon Valley Business Journal . Select employers from the Bay Area were named winners of the awards program, that is held annually. These winning organizations were honored for creating exceptional workplaces that their employees value highly. Award applicants were evaluated and ranked highest across various categories including fun, collaborative culture, solid compensation, benefits offerings, as well as management practices. "We are very honored to receive this award that spotlights our exceptional culture and amazing teams," says Divya Ghatak , Vice President of People at Nevro . "This is an especially...
May 7, 2018 Nevro Reports First Quarter 2018 Financial Results
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months ended March 31, 2018 . First Quarter Highlights: Achieved revenue of $87.6 million in the first quarter of 2018, an increase of 28% as reported, over the same period of the prior year U.S. revenue of $70.6 million in the first quarter of 2018, an increase of 33% over the prior year International revenue of $17.0 million in the first quarter of 2018, an increase of 1% in constant currency and 11% on an as-reported basis, both over the same period of the prior year Received U.S. Food & Drug Administration ( FDA ) approval for the Senza II™ Spinal Cord Stimulation (SCS) System Announced full-body magnetic resonance imaging (MRI) conditional labeling in the U.S. for the Senza SCS System Presented on clinical and scientific progress at the 2018 North American Neuromodulation Society...
May 2, 2018 Nevro to Present at the Bank of America Merrill Lynch 2018 Health Care Conference
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that its management will be presenting at the Bank of America Merrill Lynch 2018 Health Care Conference on Tuesday, May 15, 2018 in Las Vegas. Nevro management is scheduled to present at 2:20 p.m. PT.  The presentation will be accessible via a live audio webcast, accessible in the "Investors" section of the company's website at: http://www.nevro.com/investors. Following the presentation, an archived copy will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California , Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza® spinal cord stimulation (SCS) system, an evidence-based,...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.